Author:
Nanda Sony,Nayak Bhagyalaxmi,Senapati S. N.,Padhy A. K.,Nayak Mamita,Parija Jita,Mohapatra Janmejaya,Mahapatra Manoranjan
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Denny L, Herrero R, Levin C, et al. Cervical cancer. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors., et al., Cancer: Disease Control Priorities Third Edition, 3. Chicago: World Bank Publications; 2015.
2. ICO Information Centre on HPV and cancer. Human papillomavirus and related diseases in India (summary report 2019–06–17); 2019. http://cancerindia.org.in/Wpcontent/uploads/2017/11/Cervical.pdf
3. Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 2014;32:2687–90.
4. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–43.
5. Mabuchi S, Isohashi F, Yoshioka Y, et al. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010;20:834–40.